[Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
作者信息
Liu D K
出版信息
Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1980 Apr;13(4):223-6.
PMID:6790255
Abstract
摘要
相似文献
1
[Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1980 Apr;13(4):223-6.
2
[The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1989 Apr;22(2):95-8, 126-7.
3
Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
Eur J Clin Pharmacol. 1977 Apr 20;11(4):255-61. doi: 10.1007/BF00607673.
4
[Madopar in the treatment of paralysis agitans. I. Therapeutic efficacy and side-effects in 56 cases (author's transl)].
Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1980;13(3):147-50.
5
Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
Acta Endocrinol (Copenh). 1982 Mar;99(3):344-51. doi: 10.1530/acta.0.0990344.
6
7
Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
Mov Disord. 1988;3(1):37-45. doi: 10.1002/mds.870030106.
8
Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
Ann Neurol. 1978 Sep;4(3):263-7. doi: 10.1002/ana.410040313.
9
10
[Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
Riv Neurol. 1974 Sep-Oct;44(5):303-30.
Zotero 插件